SEC Form 4 · accession 0001209191-15-078843

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 4, 2015

Accepted (ET)

Nov 6, 2015 · 1:55 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Nov 4, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Nov 4, 2015	S	2,700	$123.22	D	352,984	D
Common Stock^F2,F4	Nov 4, 2015	S	3,200	$124.05	D	349,784	D
Common Stock^F2,F5	Nov 4, 2015	S	4,300	$124.92	D	345,484	D
Common Stock	Nov 4, 2015	S	200	$125.85	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$35.64	Nov 4, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	125,600	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $123.22 (range $122.58 to $123.53).
F4Open market sales reported on this line occurred at a weighted average price of $124.05 (range $123.62 to $124.48).
F5Open market sales reported on this line occurred at a weighted average price of $124.92 (range $124.65 to $125.55).
F6Fully vested.